ArticleBioinformation2026
Serum fetuin A and cystatin B as biomarkers among autism spectrum disorder patients in central India.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism Spectrum Disorder (ASD) remains underdiagnosed in low- and middle-income countries due to reliance on subjective behavioural assessments and lack of validated objective biomarkers for early detection. Therefore, it is of interest to investigate the potential of two serum biomarkers, Fetuin-A and Cystatin B, as objective diagnostic indicators for ASD in 60 children from Central India (30 with ASD, 30 controls). While Fetuin-A showed a non-significant trend of elevation in the ASD group, Cystatin B levels were found to be significantly elevated in the ASD subjects compared to the neurotypical controls. ROC analysis demonstrated moderate diagnostic potential for both, with Cystatin B showing a higher Area under the Curve (AUC) of 69.5%. Thus, Cystatin B is a promising serum biomarker that could supplement current diagnostic tools for the early and accurate identification of ASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.